Notably, only partial responses to LSD1 inhibitors were seen in sensitive SCLC cell lines, which were attributed to TEAD4 activation–acquired resistance that could be alleviated with TEAD inhibitor cotreatment (113). Here, TEAD4 is linked to small cell lung carcinoma.